autologous bone marrow transplantation

(redirected from ABMT)
Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia.

autologous bone marrow transplantation

A procedure in which haematopoietic stem cells are extracted (apheresed) from a patient with lymphoma and other cancers, who is treated with high-dose chemo- and/or radiotherapy to eliminate malignant cells in the bone marrow. The stem cells are then administered. ABMT is a standard second-line therapy for some lymphomas; it has a low risk of infection and has no risk of graft-versus-host disease, which is typical of allogeneic bone marrow transplantation. ABMT is less preferred for patients with acute myeloid leukaemia, in whom the relapse may occur as the patient’s marrow may contain malignant cells.

autologous bone marrow transplantation

Transplantation medicine The administration to an individual 'X' of his/her own BM, often to a leukemic Pt in relapse who, because a suitable HLA-matched donor is not available, would otherwise die of the disease. See Bone marrow.

autologous bone marrow transplantation

Abbreviation: ABMT
The harvesting and preservation of a patient's own blood-forming cells, followed by their eventual reintroduction into a patient. The procedure may be used to treat a variety of cancers and blood disorders. Current practice is to mobilize stem cells into the blood stream with growth factors and then to collect and filter the blood by leukapheresis. In leukapheresis stem cells are identified by a cell surface antigen called CD34. After desirable blood-forming cells with this antigen are removed from the patient's blood, high-dose chemotherapy, monoclonal antibody therapy, or radiation may be used to purge the marrow of diseased cells. Healthy CD34+ cells capable of rebuilding the bone marrow are then returned to the patient and stimulated to reproduce. Synonym: autologous hematopoietic stem cell transplantation
See also: transplantation
References in periodicals archive ?
While many health plans may have been interested in limiting coverage of ABMT for breast cancer to clinical trials, for most plans there was no contractual basis to do so, and widespread insurance coverage tends to dampen enthusiasm for participation in clinical trials.
For example, in the early recruitment period for the clinical trials, it was estimated that less than 1 percent of patients with metastatic breast cancer who received an ABMT did so within the context of a randomized clinical trial.
With coverage not restricted to clinical trials, many patients opted not to be part of a randomized study for fear of being randomized to the "standard" treatment arm, which was widely perceived to be ineffective, The initial debate regarding insurance coverage may also have influenced the perception of the superiority of the ABMT arm.
This growth of ABMT capabilities, in part stimulated by widespread insurance coverage, represents a considerable infrastructure supporting ABMT for breast cancer; it is estimated that there is now a 25 to 50 percent excess service capacity for ABMT.
One, which is illustrated in the ABMT cases, is to define the scope of the issue so narrowly that current technology assessments cannot possibly answer the question.
3) ABMT is a therapy that allows much higher doses of chemotherapy and radiation to be administered to a cancer patient than is ordinarily possible because of their toxic effects on bone marrow, which supports the immune system.
The most frequently litigated application of ABMT has been for metastatic breast cancer.
The Western Union-IBK ABMT service complements the bank's nationwide network of over 584 branches offering the Western Union[R] Money Transfer(SM) service.
Western Union-SBI ABMT complements the nationwide network of over 12,000 SBI branches currently offering the Western Union[R] Money Transfer(SM) service.
ABMT will also help unbanked consumers to be banked and completely combined into the formal financial system.
Use of this new gene therapy protocol may ultimately permit the use of higher doses of chemotherapeutic compounds, and may also reduce or eliminate the need for additional ABMT procedures following chemotherapy for recurrent cancer," commented M.